Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Orthofix Medical Inc. (OFIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.28-0.46 (-2.02%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.74
Open22.83
Bid8.92 x 800
Ask35.64 x 900
Day's Range22.13 - 22.78
52 Week Range21.66 - 43.30
Volume74,763
Avg. Volume97,059
Market Cap439.925M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-0.76
Earnings DateApr 28, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.83
  • Zacks

    Orthofix (OFIX) Beats Q2 Earnings and Revenue Estimates

    Orthofix (OFIX) delivered earnings and revenue surprises of 14.29% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Orthofix Reports Second Quarter 2022 Results

    LEWISVILLE, Texas, August 05, 2022--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2022. Net sales were $118.1 million, earnings per share ("EPS") was $0.12, and adjusted EPS was $0.08.

  • Business Wire

    Orthofix Medical and CGBio Announce Strategic Partnership Agreement for Novosis rhBMP-2 Bone Graft Solutions

    LEWISVILLE, Texas, August 02, 2022--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications. The two companies will work together for clinical development and commercialization of Novosis™ recombinant human bone morphogenetic protein-2 (rhBMP-2) bone g

Advertisement
Advertisement